

Piśmiennictwo – Nowe czynniki ryzyka nr 2(7) czerwiec 2007

Nowe biologiczne czynniki ryzyka miażdżycy

Dr hab. med. Anetta Undas

1. Yusuf S, Hawken S, Ounpun S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004;364:937-52.
2. Ridker PM, Libby P. Risk factors for atherothrombotic disease. W. Zipes, Libby, Bonow, Braunwald. Braunwald's Heart Disease. Elsevier 7th Ed. Philadelphia 2005.
3. European guidelines on cardiovascular disease prevention in clinical practice. *Eur J Cardiovasc Prev Rehab* 2003;10 suppl.1:S1-S78.
4. Yeh ETH, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. *Circulation* 2003;107:370-372.
5. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med.* 2002;347:1557-1565.
6. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med.* 2000;342:836-843. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. *Circulation* 2003;108:161-167.
7. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary artery disease. *N Engl J Med.* 2004;350:1387-1393.
8. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice. *Circulation.* 2003;107:499.
9. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. *J Am Med Assoc.* 1992;268:877-81.
10. Omland T, Samuelsson A, Hartford M, et al. Serum homocysteine concentration as an indicator of survival in patients with acute coronary syndromes. *Arch Intern Med.* 2000;160:1834-1840.
11. Facila L, Nunez JE, Bertomeu GV, et al. Early determination of homocysteine levels in acute coronary syndromes, is it an independent prognostic factor? *Int J Cardiol.* 2005;100:275-279.
12. Zylberstein DE, Bentsson C, Bjorkelund C, et al. Serum homocysteine in relation to mortality and morbidity from coronary heart disease. A 24-year follow-up of the population study of women in Gothenburg. *Circulation.* 2004;109:601-606.
13. Clarke R, Collins R, Lewington S, et al. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. *JAMA* 2002;288:2015-2022.
14. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular: evidence on causality from a meta-analysis. *Br Med J.* 2002;325:1202-1209.
15. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med.* 2006;354:1567-77.
16. Bona KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. *N Engl J Med.* 2006;354:1578-88.
17. Hobbs HH, White AL. Lipoprotein (a). Intrigues and insights. *Curr Opin Lipidol.* 1999;10:225-233.

18. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary artery disease. Meta-analysis of prospective studies. *Circulation*. 2000;102:1082-1087.
19. Albert MA, Danieson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation /CRP evaluation (PRINCE). *JAMA*. 2001;286:64-70.
20. Ma J, Hennekens CH, Ridker PM, Stampfer MJ. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. *J Am Coll Cardiol*. 1999;33:1347-1352.
21. De Stavola BL, Meade TW. Long-term effects of hemostatic variables on fatal coronary heart disease: 30-year results from the first prospective Northwick Park Heart Study (NPHS-I). *J Thromb Haemost*. 2007;5:461-71.
22. Morange PE, Bichel C, Nicaud V et al. Hemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. *Arterioscler Thromb Vasc Biol*. 2006;26:2793-9.
23. Rudnicka AR, Mt-Isa S, Meade TW. Associations of plasma fibrinogen and factor VII clotting activity with coronary heart disease and stroke: prospective cohort study from the screening phase of the Thrombosis Prevention Trial. *J Thromb Haemost*. 2006;4:2405-10.
24. Acevado M, Pearce GL, Kottke-Marchant K. Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic *Arterioscler Thromb Vasc Biol*. 2002;22:1042-1047.

Szczepienia przeciw grypie w prewencji chorób sercowo-naczyniowych

Dr hab. med. Piotr Podolec, Dr Grzegorz Kopeć

1. Johnson NPAS, Mueller J: Updating the accounts : global mortality of the 1918-20 „Spanish” influenza epidemic. *Bull Hist Med* 2002;76:105-15.
2. Azambuja MI: Spanish flu and early 20th-century expansion of a coronary heart disease – prone subpopulation. *Tex Heart Inst J* 2004;31:14-21.
3. Bondarenko SS, Tumanov FA: The effect of influenza and para-influenza on the course of ischemic heart disease. *Ter Arkh* 1992;64:81-83.
4. Spodick DH, Flessas AP, Johnson MM, et al: Association of acute respiratory symptoms with onset of acute myocardial infarction: Prospective investigation of 150 consecutive patients and matched control patients. *The American Journal of Cardiology*. 1984;53:481-482.
5. Smeeth L, Thomas SL, Hall AJ, et al: Risk of myocardial infarction and stroke after acute infection or vaccination. *N Engl J Med* 2004;351:2611-2618.
6. Madjid M, Miller Ch, Zarubaev V, et al: Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34 892 subjects. *Eur Heart J* doi:10.1093/eurheartj/ehm035
7. <http://www.who.int/csr/disease/influenza/en/>
8. Centers for disease control and prevention (CDC). Advisory committee on immunization practices. Smith NM, Bresee JS, Shay DK, et al: Prevention and control of influenza. Recommendations of the advisory committee on immunization practices (ACIP). *MMWR Recom Rep* 2006;55:1-41.
9. <http://www.pzh.gov.pl/epimeld/grypa/>
10. Davis MM, Taubert K, Benin A, et al: Influenza vaccination as secondary prevention for cardiovascular disease. A science advisory from the American Heart Association/American College of Cardiology. *Circulation* 2006;114:1459-1553.

11. Tabela 1. Naghavi M, Barlas Z, Siadaty S. et al: Association of influenza vaccination and reduced risk of recurrent myocardial infarction. *Circulation* 2000;102:3039-3045
12. Tabela 1. Lavallée P, Perchaud V, Gautier-Bertrand M. et al: Association between influenza vaccination and reduced risk of brain infarction. *Stroke* 2002;33:513-518
13. Tabela 1. Siscovick DS, Raghunathan TE, Lin D, et al: Influenza vaccination and the risk of primary cardiac arrest. *Am J Epidemiol* 2000;152:674-677.
14. Jackson LA, Yu O, Heckbert SR, et al: Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. *American Journal of Epidemiology* 2002;156:634-640
15. Gurfinkel EP, Leon de la Fuente RL, Mendiz O et al: Influenza vaccine pilot study in acute myocardial infarction and planned percutaneous coronary intervention. The Flu Vaccination Acute Coronary Syndromes (FLUVACS) Study Group. *Circulation* 2002;105:2143-8.
16. Gurfinkel EP, Leon de la Fuente RL, Mendiz O et al: Flu vaccination in acute coronary syndromes and planned coronary interventions (FLUVACS) Study. One year follow – up. *Eur Heart J* 2004;25:25-31.
17. Smith SC Jr, Allen J, Blair SN, et al: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. *Circulation*. 2006; 113: 2363–2372.
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002; 360: 7–22.
19. The Macroepidemiology of Influenza Vaccination (MIV) Study Group The macroepidemiology of influenza vaccination in 56 countries, 1997–2003. *Vaccine* 2005;23:5133–5143.
20. Madjid M, Naghavi M, Litovsky S, et al: Influenza and cardiovascular disease. A new opportunity for prevention and the need for further studies. *Circulation* 2003;108:2730-2736
21. Bouwman JJ, Visseren FL, Bosch MC, et al: Procoagulant and inflammatory response of virus-infected monocytes. *Eur J Clin Invest* 2002;32:759-766.

Komentarz dotyczący epidemiologii grypy i szczepień

Prof. dr hab. Lidia B. Brydak



Brydak L.B. Grypa i jej profilaktyka. Termedia, Poznań wyd. 2, 2004, 1-272.

Brydak L.B. Grypa problem zdrowia publicznego. *Praktyka Lekarska*, 27, 18-

Brydak L.B., Frącka M., Machała M., Szkudlarek D.: Antibody response to vaccine in children with bronchopulmonary dysplasia. *Infection*, 2001, 29(3), 181-182

4. Brydak L.B., Guzy J., Starzyk J., Machała M., Góźdz S.: Humoral immune response after vaccination against influenza in patients with breast cancer. *Supportive Care in Cancer*, 2001, 9(1), 65-68
5. Brydak L.B., Machała M. Humoral immune response to influenza vaccination in patients from high-risk groups. *Drugs*, 2000, 60(1), 35-53.
6. Brydak L.B, Machała M. Zaszczep się przeciwko grypie, aby uniknąć tragedii, jaka spotkała naszych dziadków. *Terapia, Wyd. Warsaw Voice*, 2006,1-23
7. Brydak L.B, Machała M.,: Grypa ostatnia niekontrolowana plagą ludzkości .Wyd. *Warsaw Voice*, 2006,1-16
8. Brydak L.B., Machała M., Łaguna P., Rokicka-Milewska R.: Antibody response to hemagglutinin and neuraminidase in splenectomized patients vaccinated against influenza in Poland. *Journal of Clinical Immunology*, 2004, 24(3), 225-236.



9. Brydak L.B., Machała M., Centkowski P., Warzocha K., Biliński P.: Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma. *Vaccine*, 2006, 24(44-46), 6620-6623.
10. Brydak L.B., Machała M., Myśliwska J., Myśliwski A., Trzonkowski P. Immune response to influenza vaccination in an elderly population. *Journal of Clinical Immunology*, 2003, 23(3), 214-222.
11. Brydak L.B., Rokicka-Milewska R., Machała M., Jackowska T.: Studies on the humoral immune response to hemagglutinin of influenza vaccine in children with acute lymphoblastic leukemia after chemotherapy treatment. *International J. of Pediatric Hematology/Oncology*, 2000, 7(1), 29-40.
12. Brydak L.B., Skwarczyński T., Machała M.: Antibody response to influenza vaccination in healthy adults. *Viral Immunology*, 2004, 17(4), 609-615.
13. Brydak L.B. Steciwko A.F.: Grypa. Wskazania do szczepień, możliwe powikłania .List do lekarzy. *Terapia* 2006, 9(183), 9-12.
14. Glezen W.P. Serious morbidity and mortality associated with influenza epidemics. *Epidemiol. Rev.* 1993, 4, 25-44.
15. Jahnz-Różyk K., Brydak L.B., Targowski T., Machała M., Płusa T.: Effect of influenza vaccinations on immune response and serum eotaxin level in patients with allergic bronchial asthma .*Mediators of Inflammation*, 2004, 13(3), 195-199.
16. Myśliwska J., Trzonkowski P., Szmit E., Brydak L.B., Machała M., Myśliwski A.: Immunomodulating effect of influenza vaccination in the elderly differing in health status. *Experimental Gerontology*, 2004, 39(10), 1147-145.
17. Machała M., Brydak L.B.: Program nadzoru nad grypą SENTINEL w Polsce. *Essentia Medica*, 2006, 5-6(31-32), 14-18.
18. Machała M., Wiatr E., Gawryluk D., Brydak L.B. Znaczenie diagnostyki wirusologicznej dla skuteczności leczenia hospitalizowanych pacjentów zakażonych wirusem grypy. *Pneumonologia i Alergologia Polska* 2006, II(74), 166-173.
19. Morbidity and Mortality Weekly Report. *Prevention and Control of Influenza* 2006, 55, 1-42.
20. Myśliwska J., Trzonkowski P., Szmit E., Brydak L.B., Machała M., Myśliwski A.: Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination-an impact of immunosenescence. *Vaccine*, 2003, 8, 21(25-26), 3826-3836.
21. Oxford J.S., Manuguerra J.C., Kistner O., Linde A., Kunze M., Lange W., Schweiger B., Spala G., Rebelo de Andrade H., Perez Brena P.R., Beytout J., Brydak L.B., Caraffa de Stefano D., Hungnes O., Kyncl J., Montomoli E., Gil de Miguel A., Vranckx R., Osterhaus A.: A new European perspective of influenza pandemic planning with a particular focus on the role of mammalian cell culture vaccines. *Vaccine*, 2005, 23(46-47), 5440-9.
22. World Health Organization, strona internetowa www.who.int

Grubość kompleksu intima–media tętnic szyjnych

Prof. dr hab. med. Zbigniew Gąsior

1. Barrett-Connor E, Laughlin GA, Connor C: Coronary artery calcium versus intima-media thickness as a measure of cardiovascular disease among asymptomatic adults. *Am J Cardiol* 2007; 99: 227-31.
2. Kathiresan S, Larson MG, Keyes MJ i wsp: Assessment by cardiovascular magnetic resonance, electron beam computed tomography, and carotid ultrasonography of the

- distribution of subclinical atherosclerosis across Framingham risk strata. *Am J Cardiol* 2007; 99: 310-4.
3. Howard G, Sharett AR, Heiss G i wsp: Carotid artery intimal-media thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. *Stroke* 1993; 24: 1297-1304.
 4. Hodis HN, Mack WJ, LaBree L i wsp: The role of carotid arterial intima-media thickness in predicting clinical coronary events. *Ann Intern Med* 1998; 128: 262-269.
 5. Corrado E, Rizzo M, Tantillo R i wsp: Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions. *Stroke*; 2006; 37, 482-6.
 6. Bots ML, Baldassarre D, Simon A, de Groot E, O'Leary DH, Riley W, Kastelein JJ, Grobbee DE: Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? *Eur Heart J* 2007; 28: 398-406
 7. 2003 European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens* 2003; 21: 1011-1053.
 8. Kablak-Ziembicka A, Przewłocki T, Tracz W i wsp: Gender differences in carotid intima-media thickness in patients with suspected coronary artery disease. *Am J Cardiol* 2005; 96: 1217-22.
 9. Dijk JM, van der Graaf Y, Bots ML, Grobbee DE, Algra A: Carotid intima-media thickness and the risk of new vascular events in patients with manifest atherosclerotic disease: the SMART study. *Eur Heart J* 2006; 27: 1971-8.
 10. Ogata T, Yasaka M, Yamagishi M, Seguchi O, Nagatsuka K, Minematsu K: Atherosclerosis found on carotid ultrasonography is associated with atherosclerosis on coronary intravascular ultrasonography. *J Ultrasound Med* 2005; 24: 469-474.
 11. O'Leary DH, Polak JF, Kronmal RA i wsp: Thickening of the carotid wall: a marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group. *Stroke* 1996; 27: 224-231.
 12. O'Leary DH, Polak JF, Kronmal RA i wsp: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. *N Engl J Med* 1999; 340: 14-22.
 13. Zheng L, Hodis HN, Buchanan TA i wsp: Effect of antihypertensive therapy on progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. *Am J Cardiol* 2007; 99: 956-60.
 14. Crouse JR, Raichlen JS, Riley WA i wsp: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. *JAMA* 2007; 297: 1344-53.
 15. De Backer G, Ambrosioni E, Borch-Johnsen K i wsp: European guidelines on cardiovascular disease prevention in clinical practice. *Eur J Cardiovasc Prev Rehab* 2003; 10(Suppl): S1-S78.
 16. Baldassarre D, Amato M, Pustina L i wsp: Measurement of carotid artery intima-media thickness in dyslipidemic patients increases the power of traditional risk factors to predict cardiovascular events. *Atherosclerosis* 2007; 191: 403-8.

Ocena funkcji śródbłonna (rozszerzalność tętnicy ramiennej) – związek z zaawansowaniem miażdżycy
Dr Grzegorz Kopeć, Dr hab. med. Piotr Podolec

1. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction. Testing and clinical relevance. *Circulation* 2007;115:1285-1295.

2. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. *Circulation* 2004;109(suppl III):27-32.
3. Drexler H. Factors involved in the maintenance of endothelial function. *Am J Cardiol* 1998;82:3S-4S.
4. Kinlay S, Behrendt D, Wainstein M. Role of endothelin – 1 in the active constriction of human atherosclerotic coronary arteries. *Circulation* 2001;104:1114-1118.
5. Li J, Zhao SP, Li XP, et al. Non-invasive detection of endothelial dysfunction in patients with essential hypertension. *Int J Cardiol* 1997;61:165–169.
6. Rang HP, Dale MM, Ritter JM. *Pharmacology*. Churchill Livingstone 1999.
7. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle cells by acetylcholine. *Nature* 1980;288:373-376.
8. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerosis coronary arteries. *N Engl J Med* 1986;315:1046–1051.
9. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. *Lancet* 1992;340:1111-1115.
10. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery: A Report of the International Brachial Artery Reactivity Task Force. *J Am Coll Cardiol* 2002;39:257– 265.
11. Takase B, Uehata A, Akima T, et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. *Am J Cardiol* 1998;82:1535–1539.
12.
 - a. Neunteufl T, Katzenschlager R, Hassan A, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. *Atherosclerosis* 1997;129:111-118.
 - b. Schroeder S, Enderle MD, Ossen R, et al. Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: Pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging. *Am Heart J* 1999;138:731-739.
 - c. Teragawa H, Kato M, Kurokawa J, et al. Usefulness of flow-mediated dilation of the brachial artery and/or the intima-media thickness of the carotid artery in predicting coronary narrowing in patients suspected of having coronary artery disease. *Am J Cardiol* 2001;88:1147-1151.
 - d. Jambrik Z, Venneri L, Varga A, et al. Peripheral vascular endothelial function testing for the diagnosis of coronary artery disease. *Am Heart J* 2004;148:684-689.
 - e. Kopeć G, Podolec P, Cwynar M, et al. The role of early markers of atherosclerosis in prediction of critical coronary artery stenosis. *J Hypertens* 2006;24(supl 6):68 (OS23-1).
13. Cohen JD, Drury JH, Ostdiek J, et al. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events? *Am Heart J* 2000;139(4):734-738.
14. Roman M, Naqvi T, Gardin J, et al. Clinical Application of Noninvasive Vascular Ultrasound in Cardiovascular Risk Stratification: A Report from the American Society of Echocardiography and the Society of Vascular Medicine and Biology. *J Am Soc Echocardiogr* 2006;19:943-954.

Wskaźnik uwapnienia tętnic wieńcowych (Calcium Score)

Dr hab. med. Mieczysław Pasowicz

1. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Jr. *et al.* A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation* 1995;92:1355-74.
2. Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P *et al.* Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. *Circulation* 2006;114:1761-91.
3. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. *JAMA* 2004;291:210-15.
4. Taylor AJ, Bindeman J, Feuerstein I, Cao F, Brazaitis M, O'Malley PG. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. *J.Am.Coll.Cardiol.* 2005;46:807-14.
5. Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. *J.Am.Coll.Cardiol.* 2005;46:158-65.
6. Vliegenthart R, Oudkerk M, Hofman A, Oei HH, van Dijck W, van Rooij FJ *et al.* Coronary calcification improves cardiovascular risk prediction in the elderly. *Circulation* 2005;112:572-77.
7. Lamonte MJ, Fitzgerald SJ, Church TS, Barlow CE, Radford NB, Levine BD *et al.* Coronary artery calcium score and coronary heart disease events in a large cohort of asymptomatic men and women. *Am.J.Epidemiol.* 2005;162:421-29.
8. Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. *Arch.Intern.Med.* 2004;164:1285-92.
9. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J *et al.* European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. *Eur.Heart J.* 2003;24:1601-10.
10. Haberl R, Becker A, Leber A, Knez A, Becker C, Lang C *et al.* Correlation of coronary calcification and angiographically documented stenoses in patients with suspected coronary artery disease: results of 1,764 patients. *J.Am.Coll.Cardiol.* 2001;37:451-57.
11. Budoff MJ, Diamond GA, Raggi P, Arad Y, Guerci AD, Callister TQ *et al.* Continuous probabilistic prediction of angiographically significant coronary artery disease using electron beam tomography. *Circulation* 2002;105:1791-96.
12. Knez A, Becker A, Leber A, White C, Becker CR, Reiser MF *et al.* Relation of coronary calcium scores by electron beam tomography to obstructive disease in 2,115 symptomatic patients. *Am J Cardiol* 2004;93:1150-52.
13. O'Rourke RA, Brundage BH, Froelicher VF, Greenland P, Grundy SM, Hachamovitch R *et al.* American College of Cardiology/American Heart Association Expert

Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. *Circulation* 2000;102:126-40.

14. Schuijf JD, Wijns W, Jukema JW, Decramer I, Atsma DE, de Roos A *et al.* A comparative regional analysis of coronary atherosclerosis and calcium score on multislice CT versus myocardial perfusion on SPECT. *J Nucl. Med.* 2006;47:1749-55.
15. Berman DS, Wong ND, Gransar H, Miranda-Peats R, Dahlbeck J, Hayes SW *et al.* Relationship between stress-induced myocardial ischemia and atherosclerosis measured by coronary calcium tomography. *J Am Coll Cardiol* 2004;44:923-30.

Genetyczne czynniki ryzyka chorób sercowo-naczyniowych

Dr hab. med. Maciej Malecki

1. Rose G: Familial patterns in ischaemic heart disease: *Br J Prev Soc Med* 1964, 18:75-80.
2. Hamsten A, de Faire U: Risk factors for coronary artery disease in families of young men with myocardial infarction. *Am J Cardiol* 1987, 59:14-9.
3. Sharp SD, Williams RR, Hunt SC, Schumacher MC: Coronary risk factors and the severity of angiographic coronary artery disease in members of high-risk pedigrees. *Am Heart J* 1992, 123:279-85.
4. Allen G, Harvald B, Shields J: Measures of twin concordance. *Acta Genet Stat Med* 1967, 17:475-81.
5. Berg K: Twin studies of coronary heart disease and its risk factors. *Acta Genet Med Gemellol (Roma)* 1984, 33:349-61.
6. Chaer RA, Billeh R, Massad MG: Genetics and gene manipulation therapy of premature coronary artery disease. *Cardiology* 2004, 101:122-30.
7. Austin MA, Hutter CM, Zimmern RL, Humphries SE: Familial hypercholesterolemia and coronary heart disease: a HuGE association review. *Am J Epidemiol* 2004, 160:421-9.
8. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, McCarthy BJ: Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. *J Lipid Res* 1990, 31:1337-49.
9. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat Genet.* 2003 Jun;34(2):154-6
10. Scheuner MT: Genetic evaluation for coronary artery disease. *Genet Med* 2003, 5:269-85.
11. Nordlie MA, Wold LE, Kloner RA: Genetic contributors toward increased risk for ischemic heart disease. *J Mol Cell Cardiol* 2005, 39:667-79.

Zanieczyszczenia powietrza a ryzyko chorób sercowo-naczyniowych
Prof. dr hab. med. Adam Torbicki

1. Adams HS, Nieuwenhuijsen MJ, Colvile RN, McMullen MA, Khandelwal P. Fine Particle (PM_{2.5}) Personal Exposure Levels in Transport Microenvironments, London, UK. *Sci Total Environ* 2001; **279**: 29-44.
2. Brook RD, Franklin B, Cascio W, Hong Y, Howard G, Lipsett M, Luepker R, Mittleman M, Samet J, Smith SC, Jr., Tager I. Air Pollution and Cardiovascular Disease: a Statement for Healthcare Professionals From the Expert Panel on Population and Prevention Science of the American Heart Association. *Circulation* 2004; **109**: 2655-71.
3. Chen JC, Stone PH, Verrier RL, Nearing BD, MacCallum G, Kim JY, Herrick RF, You J, Zhou H, Christiani DC. Personal Coronary Risk Profiles Modify Autonomic Nervous System Responses to Air Pollution. *J Occup Environ Med* 2006; **48**: 1133-42.
4. Dockery DW, Stone PH. Cardiovascular Risks From Fine Particulate Air Pollution. *N Engl J Med* 2007; **356**: 511-3.
5. Lanki T, Pekkanen J, Aalto P, Elosua R, Berglind N, D'Ippoliti D, Kulmala M, Nyberg F, Peters A, Picciotto S, Salomaa V, Sunyer J, Tiittanen P, von KS, Forastiere F. Associations of Traffic Related Air Pollutants With Hospitalisation for First Acute Myocardial Infarction: the HEAPSS Study. *Occup Environ Med* 2006; **63**: 844-51.
6. Lippmann M, Frampton M, Schwartz J, Dockery D, Schlesinger R, Koutrakis P, Froines J, Nel A, Finkelstein J, Godleski J, Kaufman J, Koenig J, Larson T, Luchtel D, Liu LJ, Oberdorster G, Peters A, Sarnat J, Sioutas C, Suh H, Sullivan J, Utell M, Wichmann E, Zelikoff J. The U.S. Environmental Protection Agency Particulate Matter Health Effects Research Centers Program: a Midcourse Report of Status, Progress, and Plans. *Environ Health Perspect* 2003; **111**: 1074-92.
7. Luttmann-Gibson H, Suh HH, Coull BA, Dockery DW, Sarnat SE, Schwartz J, Stone PH, Gold DR. Short-Term Effects of Air Pollution on Heart Rate Variability in Senior Adults in Steubenville, Ohio. *J Occup Environ Med* 2006; **48**: 780-8.
8. Miller KA, Siscovick DS, Sheppard L, Shepherd K, Sullivan JH, Anderson GL, Kaufman JD. Long-Term Exposure to Air Pollution and Incidence of Cardiovascular Events in Women. *N Engl J Med* 2007; **356**: 447-58.
9. Pekkanen J, Peters A, Hoek G, Tiittanen P, Brunekreef B, de HJ, Heinrich J, Ibaldu-Mulli A, Kreyling WG, Lanki T, Timonen KL, Vanninen E. Particulate Air Pollution and Risk of ST-Segment Depression During Repeated Submaximal Exercise Tests Among Subjects With Coronary Heart Disease: the Exposure and Risk Assessment for Fine and Ultrafine Particles in Ambient Air (ULTRA) Study. *Circulation* 2002; **106**: 933-8.
10. Timonen KL, Vanninen E, de HJ, Ibaldu-Mulli A, Brunekreef B, Gold DR, Heinrich J, Hoek G, Lanki T, Peters A, Tarkiainen T, Tiittanen P, Kreyling W, Pekkanen J. Effects of Ultrafine and Fine Particulate and Gaseous Air Pollution on Cardiac

Autonomic Control in Subjects With Coronary Artery Disease: the ULTRA Study. *J Expo Sci Environ Epidemiol* 2006; **16**: 332-41.

11. von KS, Peters A, Aalto P, Bellander T, Berglind N, D'Ippoliti D, Elosua R, Hormann A, Kulmala M, Lanki T, Lowel H, Pekkanen J, Picciotto S, Sunyer J, Forastiere F. Ambient Air Pollution Is Associated With Increased Risk of Hospital Cardiac Readmissions of Myocardial Infarction Survivors in Five European Cities. *Circulation* 2005; **112**: 3073-9.